Welcome to our dedicated page for Ge Healthcare Technologies SEC filings (Ticker: GEHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GE HealthCare Technologies Inc. (GEHC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation with common stock listed on Nasdaq under the symbol GEHC, GE HealthCare submits periodic and current reports that offer detail on its financial condition, governance, and significant corporate events.
Among the key documents investors often review are Form 10-K annual reports and Form 10-Q quarterly reports, which contain information on the company’s operations across its Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses. In addition, Form 8-K current reports disclose material events. Recent 8-K filings have described items such as a three-year senior unsecured term loan credit facility, the issuance of senior notes due 2028 and 2035, the intended use of proceeds in connection with an announced acquisition of Intelerad Medical Systems, quarterly financial results, and changes to the board of directors.
Investors interested in GEHC can also use this page to track other filing types, such as registration statements and, when applicable, proxy materials related to governance matters. These documents help explain the company’s capital structure, including senior notes and credit facilities, and outline covenants, events of default, and other terms referenced in the filings.
Stock Titan enhances access to GE HealthCare’s filings by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries that highlight key points in lengthy documents. This can help users quickly understand the implications of new 10-K, 10-Q, and 8-K filings, as well as monitor developments related to financing arrangements, acquisitions, and other significant events disclosed by GE HealthCare Technologies Inc.
GE HealthCare Technologies executive Roland Rott, CEO of Imaging, reported equity award activity in company stock. On February 12, 2026, he acquired 7,885 shares of common stock at $0 per share from the vesting of previously granted performance stock units after performance goals were certified. On the same date, 3,943 shares were disposed of at $79.2 per share to cover tax withholding tied to that vesting, a non-open-market transaction. After these entries, he directly owned 32,506 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc.’s Chief Technology Officer, Kass-Hout Taha, reported equity transactions in company common stock. On February 12, 2026, he acquired 23,339 shares at $0 per share through the vesting of performance stock units granted on March 1, 2023, after performance criteria were certified as met. On the same date, 7,787 shares were disposed of at $79.20 per share to cover tax withholding obligations related to this vesting. Following these transactions, he directly owned 79,655 shares of GE HealthCare common stock.
GE HealthCare Technologies’ GC & Corporate Secretary Frank R. Jimenez reported equity compensation activity involving company common stock. On February 12, 2026, he acquired 22,078 shares at $0 per share through the vesting of performance stock units granted on March 1, 2023, after performance goals were certified as met. On the same date, 8,357 shares were disposed of at $79.20 per share to cover tax withholding obligations tied to this vesting, a non‑market, tax-related transaction. Following these entries, he directly owned 81,267 shares of GE HealthCare common stock.
SACCARO JAMES reported multiple insider transaction types in a Form 4 filing for GEHC. The filing lists transactions totaling 31,180 shares at a weighted average price of $79.20 per share. Following the reported transactions, holdings were 80,256 shares.
GE HealthCare Technologies President and CEO Peter J. Arduini reported equity award activity involving company common stock. On February 12, 2026, he acquired 74,908 shares at $0 upon vesting of previously granted performance stock units, after performance goals were certified as met. On the same date, 33,445 shares were disposed of at $79.20 per share to satisfy tax withholding obligations related to this vesting. Following these transactions, Arduini directly beneficially owned 206,135 shares of GE HealthCare common stock.
Dodge & Cox has disclosed a significant holding in GE HealthCare Technologies Inc. The firm reports beneficial ownership of 31,211,229 shares of GE HealthCare common stock, representing 6.9% of the class as of 12/31/2025.
Dodge & Cox has sole power to vote 29,588,129 shares and sole power to dispose of 31,211,229 shares, with no shared voting or dispositive power. The shares are held for clients of Dodge & Cox, who have the right to receive dividends and sale proceeds. Dodge & Cox certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of GE HealthCare.
GE HealthCare Technologies Inc. files its annual report describing its 2025 performance, business structure, and key risks. The company is a global healthcare solutions provider focused on advanced medical technology, pharmaceutical diagnostics, and AI-, cloud- and software-based tools for clinicians.
GE HealthCare operates four segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics, serving hospitals and health systems in over 160 countries. The business combines large installed equipment, recurring consumables, service contracts, and digital solutions, and notes that fourth-quarter results are typically stronger due to customer spending patterns.
The company, spun off from General Electric in January 2023, reports approximately 54,000 employees, including 11,100 engineers and scientists and extensive global sales and service networks. As of June 30, 2025, non‑affiliate shareholders held common stock with an aggregate market value of about $34 billion, and 455,749,767 shares were outstanding as of January 28, 2026. The report highlights extensive regulatory, cybersecurity, competition, reimbursement, geopolitical, and data‑privacy risks that could affect future results.
GE HealthCare Technologies Inc. furnished an 8-K to announce that it issued a press release with its fourth quarter 2025 and full-year 2025 financial results. The press release, dated February 4, 2026, is included as Exhibit 99 and is provided under Item 2.02, Results of Operations and Financial Condition.
The company notes that the information in Item 2.02, including Exhibit 99, is furnished rather than filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings. The 8-K also lists Exhibit 104, the cover page formatted in Inline XBRL, and is signed by the Controller and Chief Accounting Officer.
GE HealthCare Technologies Inc. CEO, PDx Kevin Michael O'Neill reported a tax-related share withholding on common stock. On February 1, 2026, 462 shares of GE HealthCare common stock were withheld at a price of $78.97 per share to cover tax obligations associated with vesting restricted stock units.
After this transaction, O'Neill beneficially owned 22,518 shares of common stock directly. He also had an additional 59 shares reported as indirectly owned through a share incentive plan trust. The filing reflects an administrative tax withholding event rather than an open-market purchase or sale.
GE HealthCare Technologies Inc. insider filing: CEO, AVS Philip Rackliffe reported an automatic withholding of 189 shares of common stock on February 1, 2026 at $78.97 per share to cover tax obligations from vesting restricted stock units. After this tax withholding, he beneficially owns 15,393 shares of GE HealthCare common stock directly.